1
|
Guérin C, Tulasne D. Recording and classifying MET receptor mutations in cancers. eLife 2024; 13:e92762. [PMID: 38652103 PMCID: PMC11042802 DOI: 10.7554/elife.92762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 04/04/2024] [Indexed: 04/25/2024] Open
Abstract
Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. This success is the consequence of a long characterization of MET mutations in cancers, which we propose to outline in this review. MET, a receptor tyrosine kinase (RTK), displays in a broad panel of cancers many deregulations liable to promote tumour progression. The first MET mutation was discovered in 1997, in hereditary papillary renal cancer (HPRC), providing the first direct link between MET mutations and cancer development. As in other RTKs, these mutations are located in the kinase domain, leading in most cases to ligand-independent MET activation. In 2014, novel MET mutations were identified in several advanced cancers, including lung cancers. These mutations alter splice sites of exon 14, causing in-frame exon 14 skipping and deletion of a regulatory domain. Because these mutations are not located in the kinase domain, they are original and their mode of action has yet to be fully elucidated. Less than five years after the discovery of such mutations, the efficacy of a MET TKI was evidenced in NSCLC patients displaying MET exon 14 skipping. Yet its use led to a resistance mechanism involving acquisition of novel and already characterized MET mutations. Furthermore, novel somatic MET mutations are constantly being discovered. The challenge is no longer to identify them but to characterize them in order to predict their transforming activity and their sensitivity or resistance to MET TKIs, in order to adapt treatment.
Collapse
Affiliation(s)
- Célia Guérin
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 – UMR1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to TherapiesLilleFrance
| | - David Tulasne
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 – UMR1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to TherapiesLilleFrance
| |
Collapse
|
2
|
Molla A, Coll JL. [Organs-on-chips dedicated to oncology]. Med Sci (Paris) 2019; 35:419-422. [PMID: 31115320 DOI: 10.1051/medsci/2019085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Annie Molla
- Institut pour l'avancée des biosciences (IAB), équipe « thérapie ciblée, diagnostic précoce et imagerie du cancer », Inserm U1209, CNRS UMR5309, Université Grenoble Alpes, allée des Alpes, 38700 Grenoble, France
| | - Jean-Luc Coll
- Institut pour l'avancée des biosciences (IAB), équipe « thérapie ciblée, diagnostic précoce et imagerie du cancer », Inserm U1209, CNRS UMR5309, Université Grenoble Alpes, allée des Alpes, 38700 Grenoble, France
| |
Collapse
|
3
|
Saintamand A, Ghazzaui N, Issaoui H, Denizot Y. [The IgH 3'RR: Doctor Jekyll and Mister Hyde of B-cell maturation and lymphomagenesis]. Med Sci (Paris) 2017; 33:963-970. [PMID: 29200394 DOI: 10.1051/medsci/20173311013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
The four transcriptional enhancers located in the 3' regulatory region (3'RR) of the IgH locus control the late phases of B-cell maturation, namely IgH locus transcription, somatic hypermutation and class switch recombination. Doctor Jekyll by nature, the 3'RR acts as Mister Hyde in case of oncogenic translocation at the IgH locus taking under its transcriptional control the translocated oncogene. The aim of this review is to show this duality on the basis of the latest scientific advances in the structure and function of the 3'RR and to hIghlight the targeting of the 3'RR as a potential therapeutic approach in mature B-cell lymphomas.
Collapse
Affiliation(s)
- Alexis Saintamand
- UMR CNRS 7276, Université de Limoges, rue Pr Descottes, 87025 Limoges, France
| | - Nour Ghazzaui
- UMR CNRS 7276, Université de Limoges, rue Pr Descottes, 87025 Limoges, France
| | - Hussein Issaoui
- UMR CNRS 7276, Université de Limoges, rue Pr Descottes, 87025 Limoges, France
| | - Yves Denizot
- UMR CNRS 7276, Université de Limoges, rue Pr Descottes, 87025 Limoges, France
| |
Collapse
|
4
|
Larbouret C, Gaborit N, Poul MA, Pèlegrin A, Chardès T. [The HER3/ERBB3 receptor: the dark side of the ERBB planet]. Med Sci (Paris) 2015; 31:465-8. [PMID: 26059291 DOI: 10.1051/medsci/20153105002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Christel Larbouret
- IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France
| | - Nadège Gaborit
- Department of biological regulation, Weizmann Institute of Science, Rehovot, 76100, Israël
| | - Marie-Alix Poul
- IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France
| | - André Pèlegrin
- IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France
| | - Thierry Chardès
- IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France
| |
Collapse
|